Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-part, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD0715 in Healthy Human Volunteers and Participants With Axial Spondyloarthritis

NCT07047703 is registered in ClinicalTrials.gov with Grey Wolf Therapeutics as lead sponsor.

NCT NCT07047703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07047703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-part, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD0715 in Healthy Human Volunteers and Participants With Axial Spondyloarthritis
Lead sponsor
Grey Wolf Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 28, 2025
Completion date
September 30, 2028
Enrollment
140 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis (axspa)